AOD-9604 vs Tesamorelin for Fat Loss: Mechanism, Evidence, Cost, and Which One Fits

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Current pricing always lives on each product page; the table is a guide to which product fits which goal.

The real difference is evidence, not strength

No study has measured both in the same people, so "which burns more fat" has no answer. What can be said is that tesamorelin has human trials reporting a reduction in one specific kind of fat, visceral fat, measured on CT, while the scale barely moved. AOD-9604 was tested properly for weight loss and did not separate from placebo. Neither is a weight-loss drug in the sense most people mean, and the medication with that evidence is a GLP-1.

The SHRED Blend does contain AOD-9604. Each 5 mL vial holds 10 mg AOD-9604, 6 mg CJC-1295, 10 mg ipamorelin and 10 mg MOTS-c, and the standard 0.25 mL dose delivers 0.5 mg AOD-9604, 0.3 mg CJC-1295, 0.5 mg ipamorelin and 0.5 mg MOTS-c. SHRED does not contain tesamorelin. Its growth hormone signal comes from CJC-1295, a modified GHRH analogue, paired with ipamorelin at the ghrelin receptor.

The only difference is the GHRH analogue. Tesamorelin has randomised trials in abdominal fat; CJC-1295 has human pharmacology reporting sustained growth hormone and IGF-1 rises in healthy adults but no outcome trials. A physician who wants the better-evidenced GHRH signal alongside AOD-9604 will usually prefer PHYSIQ. Neither blend has been studied as a blend. The full breakdown is in what is SHRED.

Tirzepatide works in a completely different way: it acts on gut-hormone receptors to reduce appetite, and the branded product has large randomised human trials with weight as the primary endpoint. Neither AOD-9604 nor tesamorelin acts on appetite.

Some prescribers do combine them. With tesamorelin, the rationale given is that the GLP-1 addresses total weight while tesamorelin addresses visceral fat. With AOD-9604, there is no reason from the evidence to expect it to add to a GLP-1's effect, and the GLP-1 is the one with the evidence. No trial has tested either combination, and no trial shows that a growth hormone secretagogue preserves lean mass during GLP-1 treatment. Your physician sets your directions after reviewing your intake and your full medication list. What is tirzepatide covers the GLP-1 side.

The two are in completely different regulatory positions.

The approved tesamorelin product's label states that long-term cardiovascular safety has not been established and that it is not indicated for weight-loss management. Compounded tesamorelin shares the active peptide but is not that product; it is prepared by a state-licensed pharmacy to an individual prescription, the trial data belongs to the approved product at its approved doses, and prescribing it for anything other than the approved indication is off-label.

For AOD-9604, some sources claim FDA "GRAS" status. As of September 2026 there is no GRAS notice for AOD-9604 in the FDA's inventory, and it would have no bearing on a prescription injection in any case. Both remain legal to prescribe and dispense as compounded medications, and compounded medications are not FDA approved. Are peptides FDA approved explains the difference.

Both are injected under the skin (subcutaneously), rotating sites, five days a week with weekends off. The volume is the same, 0.25 mL, which is 25 units on a U-100 insulin syringe, and from the standard 10 mg vials it delivers 0.5 mg of either. A 15 mg / 5 mL strength exists for each, which delivers 0.75 mg in the same volume. You do not need to calculate anything: your physician sets your directions after reviewing your intake, and they are printed on the vial.

Timing differs. Tesamorelin is taken at bedtime, because the body's largest natural growth hormone pulse happens during deep sleep and the dose amplifies a pulse already under way. AOD-9604 is directed once daily; some prescribers direct it in the morning before eating. Twenty doses per vial covers about four weeks, which is why refills run every 28 days, one vial at a time. Both ship refrigerated with ice packs and stay in the fridge between doses; do not shake the tesamorelin vial. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Tesamorelin. The approved product's label pools data from 740 treated patients. Effects more frequent than placebo were injection-site reactions (17% versus 6%), joint pain (13% versus 11%), pain in the extremities, muscle aches and swelling of the ankles or hands (each 6%), and tingling (5%); hypersensitivity reactions occurred in 4%. Those figures are at 2 mg daily, four times the standard compounded dose. Fluid retention, joint aches and hand tingling are classic growth hormone effects and usually mean the dose is higher than the person needs. The label also records new-onset diabetes in 5% of treated patients against 1% on placebo, so existing diabetes or borderline glucose needs discussing.

AOD-9604. The six company trials give it more human safety data than most compounded peptides. Intravenous dosing was associated with headache, fatigue, dizziness and low blood sugar; oral dosing with headache, diarrhoea, flatulence, increased appetite and nausea, more so at the highest dose. Adverse events were similarly distributed between peptide and placebo. With the injection, prescribers mostly report injection-site redness or bruising. No human trial has used the subcutaneous route.

For both, stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing.

Tesamorelin has real human trials reporting a reduction in visceral fat, measured on CT, in people with HIV and in one trial of 60 abdominally obese adults without HIV, at doses higher than the compounded vial and with scale weight largely unchanged. Visceral fat drifted back toward baseline after stopping. AOD-9604 has a clean safety record from oral and intravenous trials and a negative result for weight loss, and nothing at all for the subcutaneous route. Any provider describing AOD-9604 as a trial-backed fat-burner is describing trials that reached the opposite conclusion. Neither replaces diet, training and sleep.

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a state-licensed, FDA-registered US pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes AOD-9604 and the SHRED Blend in all 50 states and DC. Step-by-step pages: how to get AOD-9604 prescribed online, how to get tesamorelin prescribed online, how to get the SHRED Blend prescribed online and how to get tirzepatide prescribed online.